This marks AbbVie’s second major siRNA deal following its $1.4bn acquisition of Aliada Therapeutics last year.

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial, reinforcing its ...

If approved, the company is confident in its ability to Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA ...

In its second R&D alliance this week, Eli Lilly has formed a partnership with ... interfering RNA-based therapies for chronic diseases, including lepodisiran for cardiovascular disease and ...

lepodisiran, is expected to protect millions of people from heart attacks and strokes by lowering a little-known risk factor in the blood. Made by pharmaceutical giant Eli Lilly, the drug lowers ...

That may soon change. On Sunday, researchers announced that an experimental drug from Eli Lilly, lepodisiran, reduced levels of Lp(a) by a staggering 94% in a mid-stage clinical trial. The effects ...

There is a new drug out "lepodisiran" that is in the early phases ... It still will have a certain group it targets. Yet Eli Lilly will likely try to market it for who knows what.

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...

Eli Lilly ( NYSE: LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ( ...